当前新冠疫苗简介。 - Suppr

Suppr

超能文献

Profiles of current COVID-19 vaccines.

作者信息

Heinz Franz X, Stiasny Karin

机构信息

Center for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.

出版信息

Wien Klin Wochenschr. 2021 Apr;133(7-8):271-283. doi: 10.1007/s00508-021-01835-w. Epub 2021 Mar 16.

DOI:10.1007/s00508-021-01835-w

PMID:33725201

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7962631/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/050e/8064987/d669d45e6d8a/508_2021_1835_Fig1_HTML.jpg

相似文献

Profiles of current COVID-19 vaccines.当前新冠疫苗简介。

Wien Klin Wochenschr. 2021 Apr;133(7-8):271-283. doi: 10.1007/s00508-021-01835-w. Epub 2021 Mar 16.

Letter to the editor: More data on vaccine efficacy/effectiveness of COVID-19 vaccines against asymptomatic SARS-CoV-2 infection.致编辑的信：关于新冠病毒疫苗对无症状SARS-CoV-2感染的效力/效果的更多数据

Euro Surveill. 2021 Sep;26(35). doi: 10.2807/1560-7917.ES.2021.26.35.2100826.

Authors' response: Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: More data on asymptomatic SARS-CoV-2 infection.作者回应：新冠病毒疫苗对严重急性呼吸综合征冠状病毒2感染的有效性和效果：关于无症状严重急性呼吸综合征冠状病毒2感染的更多数据

Euro Surveill. 2021 Sep;26(35). doi: 10.2807/1560-7917.ES.2021.26.35.2100832.

Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.用不同佐剂增强的亚单位 SARS-CoV-2 S1 黏膜疫苗免疫仓鼠对 COVID-19 疾病的保护作用。

Front Immunol. 2023 Mar 20;14:1154496. doi: 10.3389/fimmu.2023.1154496. eCollection 2023.

COVID-19 vaccines and decreased transmission of SARS-CoV-2.COVID-19 疫苗与 SARS-CoV-2 传播减少。

Inflammopharmacology. 2021 Oct;29(5):1357-1360. doi: 10.1007/s10787-021-00847-2. Epub 2021 Jul 19.

Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.针对 SARS-CoV-2 及其变体的多样化疫苗平台。

Expert Rev Vaccines. 2022 Jan;21(1):47-67. doi: 10.1080/14760584.2022.1997601. Epub 2022 Jan 11.

Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.临床试验中 SARS-CoV-2 疫苗的免疫原性和安全性。

Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.

Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India.印度奥里萨邦疫苗突破性新冠病毒毒株的基因组概况。

Int J Infect Dis. 2022 Jun;119:111-113. doi: 10.1016/j.ijid.2022.03.042. Epub 2022 Mar 28.

SARS-CoV-2 vaccine candidates in rapid development.正在快速开发的 SARS-CoV-2 疫苗候选物。

Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29.

The future of tumor vaccines in the post-COVID-19 era-Current challenges.新冠疫情后时代肿瘤疫苗的未来——当前挑战

Immun Inflamm Dis. 2021 Dec;9(4):1795-1797. doi: 10.1002/iid3.521. Epub 2021 Sep 2.

引用本文的文献

Genomic surveillance and serological profile of SARS-CoV-2 variants circulating in Macaé and nearby cities, southeastern Brazil.巴西东南部马卡埃及附近城市中流行的新冠病毒变异株的基因组监测和血清学特征

Front Microbiol. 2024 Apr 30;15:1386271. doi: 10.3389/fmicb.2024.1386271. eCollection 2024.

T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets.针对 SARS-CoV-2 的 T 细胞免疫：如果已知的最佳方法从长远来看并非最优方案，那该怎么办？适应不断变化的靶标。

Front Immunol. 2023 Jun 14;14:1133225. doi: 10.3389/fimmu.2023.1133225. eCollection 2023.

Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study.接种 COVID-19 疫苗后急性中枢神经系统炎症：一项观察性队列研究。

Mult Scler. 2023 Apr;29(4-5):595-605. doi: 10.1177/13524585231154780. Epub 2023 Feb 25.

Examination of Preferences for COVID-19 Vaccines in Hungary Based on Their Properties-Examining the Impact of Pandemic Awareness with a Hybrid Choice Approach.基于特性的匈牙利人对 COVID-19 疫苗的偏好研究——用混合选择法检验大流行意识的影响。

Int J Environ Res Public Health. 2023 Jan 10;20(2):1270. doi: 10.3390/ijerph20021270.

Adaptation-proof SARS-CoV-2 vaccine design.抗适应性严重急性呼吸综合征冠状病毒2疫苗设计

Adv Funct Mater. 2022 Dec 2;32(49). doi: 10.1002/adfm.202206055. Epub 2022 Oct 3.

Assessment of SARS-CoV-2 vaccination status in SARS-COV-2 infected patients admitted in Dr Ruth K.M. Pfau, Civil Hospital Karachi.对卡拉奇市民医院鲁思·K·M·普法夫医生收治的新冠病毒感染患者的新冠病毒疫苗接种状况评估。

Pak J Med Sci. 2022 Nov-Dec;38(8):2089-2094. doi: 10.12669/pjms.38.8.5733.

A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants.关于当前疫苗及其对抗新冠病毒变异株效力的综合综述。

Vaccines (Basel). 2022 Oct 2;10(10):1655. doi: 10.3390/vaccines10101655.

How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变种如何逃避宿主的保护性免疫并介导发病机制？

Bull Natl Res Cent. 2022;46(1):255. doi: 10.1186/s42269-022-00945-3. Epub 2022 Oct 12.

SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge.SARS-CoV-2 病毒样颗粒由单个重组杆状病毒产生，可产生抗 S 抗体并预防变异株挑战。

Viruses. 2022 Apr 27;14(5):914. doi: 10.3390/v14050914.

Relationship between blood clots and COVID-19 vaccines: A literature review.血凝块与新冠疫苗之间的关系：一篇文献综述。

Open Life Sci. 2022 Apr 26;17(1):401-415. doi: 10.1515/biol-2022-0035. eCollection 2022.

本文引用的文献

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.由ChAdOx1 nCoV-19/AZD1222疫苗表达的类天然严重急性呼吸综合征冠状病毒2刺突糖蛋白

ACS Cent Sci. 2021 Apr 28;7(4):594-602. doi: 10.1021/acscentsci.1c00080. Epub 2021 Apr 2.

Future considerations for the mRNA-lipid nanoparticle vaccine platform.mRNA-脂质纳米颗粒疫苗平台的未来考量。

Curr Opin Virol. 2021 Jun;48:65-72. doi: 10.1016/j.coviro.2021.03.008. Epub 2021 Apr 24.

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.识别 SARS-CoV-2 刺突蛋白 N 端结构域的中和性和保护性人源单克隆抗体。

Cell. 2021 Apr 29;184(9):2316-2331.e15. doi: 10.1016/j.cell.2021.03.029. Epub 2021 Mar 16.

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.N 端结构域抗原性分析揭示了 SARS-CoV-2 的一个弱点。

Cell. 2021 Apr 29;184(9):2332-2347.e16. doi: 10.1016/j.cell.2021.03.028. Epub 2021 Mar 16.

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.基于复制缺陷型 Ad26 病毒载体的疫苗：标准化模板及风险/获益评估的关键考虑因素。

Vaccine. 2021 May 21;39(22):3081-3101. doi: 10.1016/j.vaccine.2020.09.018. Epub 2020 Oct 3.

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。

Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.两价 spike 纳米颗粒疫苗可保护猕猴免受 SARS-CoV-2 感染。

Cell. 2021 Mar 4;184(5):1188-1200.e19. doi: 10.1016/j.cell.2021.01.035. Epub 2021 Jan 26.

Could mixing COVID vaccines boost immune response?混合接种新冠疫苗能增强免疫反应吗？

Nature. 2021 Feb;590(7846):375-376. doi: 10.1038/d41586-021-00315-5.

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。

Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.

J&J's one-shot COVID vaccine offers hope for faster protection.强生公司的单剂新冠疫苗为更快获得保护带来了希望。

Nature. 2021 Jan 29. doi: 10.1038/d41586-021-00119-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验